

Table 1: Number of Phase II trials receiving NIH funding by presence of biomarker

	No funding	NIH funding	Total
No biomarker	25511	815	26326
Biomarker	15480	785	16265
Total	40991	1600	42591

Table 2: Percentage of Phase II trials receiving NIH funding by presence of biomarker

	No funding	NIH funding	Total
No biomarker	96.9	3.1	100.0
Biomarker	95.2	4.8	100.0
Total	96.2	3.8	100.0

Table 3: Percentage of Phase II trials receiving NIH funding by biomarker role

	(1) Disease	(2) Therapeutic_Effect	(3) Toxic_Effect	(4) Not_Determined
Percentage receiving funding	6.30 (0.39)	5.04 (0.19)	2.15 (0.39)	2.94 (2.06)
Observations	3795	13267	1394	68

Standard errors in parentheses

Table 4: Percentage of Phase II trials receiving NIH funding by biomarker type

	(1)	(2)	(3)	(4)	(5)	(6)	(7)
	genomic	proteomic	biochemical	cellular	physiological	structural	anthropomorphic
Percentage receiving funding	5.65 (0.22)	5.44 (0.21)	4.16 (0.29)	7.06 (0.50)	2.22 (0.23)	3.85 (0.55)	2.64 (0.46)
Observations	10850	11314	4732	2650	4238	1221	1210

Standard errors in parentheses

Table 5: Percentage of Phase II trials receiving NIH funding by presence of biomarker

	(1)	(2)
	No_ biomarker	Biomarker
Start Year=1995	6.02	3.45
Start Year=1996	4.17	7.69
Start Year=1997	7.35	10.00
Start Year=1998	5.31	9.09
Start Year=1999	6.13	15.13
Start Year=2000	5.54	8.99
Start Year=2001	4.56	10.86
Start Year=2002	4.05	8.85
Start Year=2003	3.47	6.27
Start Year=2004	4.92	7.22
Start Year=2005	4.23	7.36
Start Year=2006	2.95	8.38
Start Year=2007	2.48	6.73
Start Year=2008	2.88	4.90
Start Year=2009	2.53	4.65
Start Year=2010	1.26	4.06
Start Year=2011	1.20	3.46
Start Year=2012	1.11	2.89
Start Year=2013	2.14	3.81
Start Year=2014	1.81	2.93
Start Year=2015	2.63	3.38

